Sarepta Therapeutics Inc Q4 2021 Earnings Call Summary - Thomson StreetEvents

Sarepta Therapeutics Inc Q4 2021 Earnings Call Summary

Sarepta Therapeutics Inc Q4 2021 Earnings Call Summary - Thomson StreetEvents
Sarepta Therapeutics Inc Q4 2021 Earnings Call Summary
Published Mar 01, 2022
23 pages (13578 words) — Published Mar 01, 2022
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of SRPT.OQ earnings conference call or presentation 1-Mar-22 9:30pm GMT

  
Brief Excerpt:

...A. Highlights: Among thousands of public and private biotech companies currently existing in US and globally, SRPT sits in select and small group of fully integrated commercial-stage biotech enterprises with proven track record of translating brilliant science into approved therapies. 1. SRPT is supporting patient community and physicians in gaining and maintaining access to those approved therapies. a. b. This operational focus and commitment to patients was on full display throughout 2021. 2. Has greater than 40 programs in pipeline of potentially life-enhancing therapies focused on rare genetic diseases across multiple platforms including: RNA. a. b. Gene therapy. c. Gene editing. 3. More than that, in 2021, Co. entered pivotal registrational trials for its lead programs in RNA and gene therapy platforms. With encouraging data from MOMENTUM Part A study, commenced Part B of the study, a pivotal trial for SRP-5051, Co.'s next-generation RNA-based PPMO for treatment of Duchenne patients...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Sarepta Therapeutics Inc
Ticker
SRPT.OQ
Time
9:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Gil Joseph Blum - Needham & Company, LLC, Research Division - Analyst : So maybe focusing a little on the PPMOs here. So you guys have never taken a price increase on your PMO franchise. But considering the potential for an improved clinical benefit of 5051, would there be discussions around this? Is this even something you're considering? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 01, 2022 / 9:30PM, SRPT.OQ - Q4 2021 Sarepta Therapeutics Inc Earnings Call

Question: Yun Zhong - BTIG, LLC, Research Division - Analyst : So my question is a follow-up one on PPMO platform. And with a better clinical profile, how possible do you think the platform can potentially expand the patient population, convincing those patients who are not committed to receiving exon skipping therapies to get on treatment? And given that you said that EXONDYS 51 and maybe even VYONDYS 53, the sales are nearing plateauing. So if you -- I know that you are very confident in the gene therapy program, but if you do decide to work on additional candidates, how fast do you think you can move the next one into the clinic? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 01, 2022 / 9:30PM, SRPT.OQ - Q4 2021 Sarepta Therapeutics Inc Earnings Call

Question: Zhiqiang Shu - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : I want to ask about your 2025 revenue aspiration of $4 billion. I think you just look at the consensus right now is $2.2 billion, $2.3 billion. What do you think the Street is missing here? And what do you think that the delta can be accounted for?

Table Of Contents

Sarepta Therapeutics Inc Q1 2022 Earnings Call Summary – 2022-05-04 – US$ 54.00 – Edited Brief of SRPT.OQ earnings conference call or presentation 4-May-22 8:30pm GMT

Sarepta Therapeutics Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript – 2022-03-31 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 31-Mar-22 4:00pm GMT

Sarepta Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript – 2022-03-15 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 15-Mar-22 7:20pm GMT

Sarepta Therapeutics Inc at Cowen Health Care Conference (Virtual) Transcript – 2022-03-09 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 9-Mar-22 7:10pm GMT

Sarepta Therapeutics Inc Q4 2021 Earnings Call Transcript – 2022-03-01 – US$ 54.00 – Edited Transcript of SRPT.OQ earnings conference call or presentation 1-Mar-22 9:30pm GMT

Sarepta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) and Q&A Session Transcript – 2022-01-10 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 10-Jan-22 3:30pm GMT

Sarepta Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference Transcript – 2021-11-30 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 30-Nov-21 6:25pm GMT

Sarepta Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript – 2021-11-15 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 15-Nov-21 8:00pm GMT

Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript – 2021-11-09 – US$ 54.00 – Edited Transcript of SRPT.OQ presentation 9-Nov-21 5:10pm GMT

Sarepta Therapeutics Inc Q3 2021 Earnings Call Summary – 2021-11-03 – US$ 54.00 – Edited Brief of SRPT.OQ earnings conference call or presentation 3-Nov-21 8:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Sarepta Therapeutics Inc Q4 2021 Earnings Call Summary" Mar 01, 2022. Alacra Store. May 18, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2021-Sarepta-Therapeutics-Inc-Earnings-Call-B15129022>
  
APA:
Thomson StreetEvents. (2022). Sarepta Therapeutics Inc Q4 2021 Earnings Call Summary Mar 01, 2022. New York, NY: Alacra Store. Retrieved May 18, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2021-Sarepta-Therapeutics-Inc-Earnings-Call-B15129022>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.